WIN 55,212-2, agonist of cannabinoid receptors, prevents amyloid β1-42 effects on astrocytes in primary culture

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Aguirre Rueda, Diana ^a   Guerra Ojeda, Sol ^a   Aldasoro, Martin ^a   Iradi, Antonio ^a   Obrador, Elena ^a   Mauricio, Maria D ^a   Vila, Jose Ma ^a   Marchio, Patricia ^a   Valles, Soraya L ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; AMYLOID BETA PROTEIN[1-42]; AUTACOID; CANNABINOID RECEPTOR; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLOOXYGENASE 2; GLIAL FIBRILLARY ACIDIC PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BENZOXAZINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CANNABINOID RECEPTOR AGONIST; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; NOS2 PROTEIN, RAT; PEPTIDE FRAGMENT; RELA PROTEIN, RAT; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ASTROCYTE; CELL VIABILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FETUS; MTT ASSAY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN CORTEX; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION;

AMYLOID BETA-PEPTIDES; ANIMALS; ASTROCYTES; BENZOXAZINES; CALCIUM CHANNEL BLOCKERS; CANNABINOID RECEPTOR AGONISTS; CELL SURVIVAL; CEREBRAL CORTEX; CYCLOOXYGENASE 2; FETUS; GENE EXPRESSION REGULATION; INTERLEUKIN-1BETA; MORPHOLINES; NAPHTHALENES; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PPAR GAMMA; PRIMARY CELL CULTURE; RATS; RECEPTORS, CANNABINOID; SIGNAL TRANSDUCTION; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84928911530     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122843     Document Type: Article

References (93)

1. Selkoe DJ. Alzheimer's disease: genotypes, phenotypes, and treatments. Science. 1977; 275: 630-631.
2. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Alzheimer's Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005; 366: 2112-2117. PMID: 16360788
3. Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol. 2007; 184: 69-91. PMID: 17222916
4. Pratico D. Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows. Ann N Y Acad Sci. 2008; 1147: 70-78. doi: 10.1196/annals.1427.010 PMID: 19076432
5. Inestrosa NC, Reyes AE, Chacón MA, Cerpa W, Villalón A, Montiel J, et al. Human-like rodent amyloid-beta-peptide determines Alzheimer pathology in aged wild-type Octodon degu. Neurobiol Aging. 2005; 26: 1023-1028. PMID: 15748782
6. Vallés SL, Borrás C, Gambini J, Furriol J, Ortega A, Sastre J, et al. Oestradiol or genistein rescues neurons from amyloid beta-induced cell death by inhibiting activation of p38. Aging Cell. 2008; 7: 112-118. PMID: 18031570
7. Sofroniew MV and Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010; 119: 7-35. doi: 10.1007/s00401-009-0619-8 PMID: 20012068
8. Choi SS, Lee HJ, Lim I, Satoh J, Kim SU. Human astrocytes: secretome profiles of cytokines and chemokines. PLoS One. 2014;1: 9(4):e92325. doi: 10.1371/journal.pone.0092325
9. van Kralingen C, Kho DT, Costa J, Angel CE, Graham ES. Exposure to inflammatory cytokines IL-1β and TNFα induces compromise and death of astrocytes; implications for chronic neuroinflammation. PLoS One. 2013;19; 8(12): e84269. doi: 10.1371/journal.pone.0084269
10. Zhang W, Smith C, Howlett C, Stanimirovic D. Inflammatory activation of human brain endothelial cells by hypoxic astrocytes in vitro is mediated by IL-1beta. J Cereb Blood Flow Metab. 2000; 20: 967-978. PMID: 10894180
11. Li C, Zhao R, Gao K, Wei Z, Yin MY, Lau LT et al. Astrocytes: implications for neuroinflammatory pathogenesis of Alzheimer's disease. Curr Alzheimer Res. 2011; 8: 67-80. PMID: 21143158
12. Valles SL, Dolz-Gaiton P, Gambini J, Borras C, Lloret A, Pallardo FV. Estradiol or genistein prevent Alzheimer's disease-associated inflammation correlating with an increase PPAR gamma expression in cultured astrocytes. Brain Res. 2010; 1312: 138-144. doi: 10.1016/j.brainres.2009.11.044 PMID: 19948157
13. Pacher P, Kunos G. Modulating the endocannabinoid system in human health and disease-successes and failures. FEBS J. 2013; 280: 1918-1943. doi: 10.1111/febs.12260 PMID: 23551849
14. 1 receptor blockade in the treatment of visceral obesity and its cardiometabolic complications. Br J Pharmacol. 2011; 163: 1423-1431. doi: 10.1111/j.1476-5381.2011.01352.x PMID: 21434882
15. Centonze D, Finazzi-Agrò A, Bernardi G, Maccarrone M. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci. 2007; 28: 180-187. PMID: 17350694
16. Klein WK. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol. 2005; 5: 400-411. PMID: 15864274
17. Hillard CJ, Weinlander KM, Stuhr KL. Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience. 2012; 1: 207-229.
18. Guindon J, Hohmann AG. The endocannabinoid system and cancer: therapeutic implication. Br J Pharmacol. 2011; 163: 1447-1463. doi: 10.1111/j.1476-5381.2011.01327.x PMID: 21410463
19. Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci. 2005; 25: 1904-1913. PMID: 15728830
20. Esposito G, Scuderi C, Savani C, Steardo L Jr, De Filippis D, Cottone P, et al. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br J Pharmacol. 2007; 151: 1272-1279. PMID: 17592514
21. Blanchard BJ, Chen A, Rozeboom LM, Stafford KA, Weigele P, Ingram VM. Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule. Proc Natl Acad Sci. 2004; 101: 14326-14332. PMID: 15388848
22. McGeer PL, McGeer EG. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol. 2013; 126: 479-497. doi: 10.1007/s00401-013-1177-7 PMID: 24052108
23. Rönicke R, Klemm A, Meinhardt J, Schröder UH, Fändrich M, Reymann KG. Abeta mediated diminution of MTT reduction - an artefact of single cell culture?. PLoS One. 2008; 3: e3236. doi: 10.1371/journal.pone.0003236 PMID: 18800168
24. Palanca JM, Aguirre-Rueda D, Granell MV, Aldasoro M, Garcia A, Iradi A. Sugammadex, a neuromuscular blockade reversal agent, causes neuronal apoptosis in primary cultures. Int J Med Sci. 2013; 10: 1278-1285. doi: 10.7150/ijms.6254 PMID: 23983586
25. Peterson GL. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem. 1977; 83: 346-356. PMID: 603028
26. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998; 391: 79-82. PMID: 9422508
27. Eikelenboom P, van Gool WA. Neuroinflammatory perspectives on the two faces of Alzheimer's disease. J Neural Transm. 2004; 111: 281-294. PMID: 14991455
28. Zhu X, Smith MA, Perry G, Aliev G. Mitochondrial failures in Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2004; 19: 345-352. PMID: 15633943
29. Jiménez-Jiménez FJ, Alonso-Navarro H, Ayuso-Peralta L, Jabbour-Wadih T. Oxidative stress and Alzheimer's disease. Rev Neurol. 2006; 42: 419-427. PMID: 16602059
30. Quintanilla RA, Orellana JA, von Bernhardi R. Understanding risk factors for Alzheimer's disease: interplay of neuroinflammation, connexin-based communication and oxidative stress. Arch Med Res. 2012; 43: 632-644. doi: 10.1016/j.arcmed.2012.10.016 PMID: 23142264
31. Milton NG. Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide. Neurosci Lett. 2002; 332: 127-130. PMID: 12384227
32. Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem. 2004; 89: 134-141. PMID: 15030397
33. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002; 1: 530-534.
34. Gómez Del Pulgar T, De Ceballos ML, Guzmán M, Velasco G. Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J. Biol. Chem. 2002; 277: 36527-36533. PMID: 12133838
35. Pourkhalili N, Ghahremani MH, Farsandaj N, Tavajohi S, Majdzadeh M, Parsa M, et al. Evaluation of anti-invasion effect of cannabinoids on human hepatocarcinoma cells. Toxicol Mech Methods. 2013; 23: 120-126. doi: 10.3109/15376516.2012.730559 PMID: 22978792
36. De Petrocellis L, Ligresti A, Schiano Moriello A, Iappelli M, Verde R, Stott CG, et al. Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. Br J Pharmacol. 2013; 168: 79-102. doi: 10.1111/j.1476-5381.2012.02027.x PMID: 22594963
37. Vara D, Salazar M, Olea-Herrero N, Guzmán M, Velasco G, Díaz-Laviada I. Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ. 2011; 18: 1099-1111. doi: 10.1038/cdd.2011.32 PMID: 21475304
38. Rocha FC, Dos Santos JG Júnior, Stefano SC, da Silveira DX. Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas. J Neurooncol. 2014: 116: 11-24. doi: 10.1007/s11060-013-1277-1 PMID: 24142199
39. Sánchez C, Galve-Roperh I, Canova C, Brachet P, Guzmán M. Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett. 1998; 436: 6-10. PMID: 9771884
40. Guzmán M, Sánchez C, Galve-Roperh I. Cannabinoids and cell fate. Pharmacol Ther. 2002; 95: 175-184. PMID: 12182964
41. Stella N. Cannabinoid signaling in glial cells. Glia. 2004; 48: 267-277. PMID: 15390110
42. Sheng WS, Hu S, min X, Cabral GA, Lokensgard JR, Peterson P. Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta.stimulated human astrocytes. Glia. 2005; 49: 211-219. PMID: 15390091
43. Palmer SL, Thakur GA, Makriyannis A. Cannabinergic ligands. Chem Phys Lipids. 2002; 121: 3-19. PMID: 12505686
44. Fakhfouri G, Ahmadiani A, Rahimian R, Grolla AA, Moradi F, Haeri A. WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway. Neuropharmacology. 2012; 63: 653-666 doi: 10.1016/j.neuropharm.2012.05.013 PMID: 22634229
45. Strohmeyer R, Rogers J. Molecular and cellular mediators of Alzheimer's disease inflammation. J Alzheimers Dis. 2001; 3: 131-157. PMID: 12214082
46. Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease-A doubleedged sword. Neuron. 2002; 35: 419-432. PMID: 12165466
47. Griffin WS, Mrak RE. Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease. J Leukoc Biol. 2002; 72: 233-238. PMID: 12149413
48. McGeer PL, Rogers J, McGeer EG. Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J Alzheimers Dis. 2006; 9: 271-276. PMID: 16914866
49. Allan SM, Rothwell NJ. Cytokines and acute neurodegeneration. Nat Rev Neurosci. 2001; 2: 734-744. PMID: 11584311
50. Allan SM, Rothwell NJ. Inflammation in central nervous system injury. Philos Trans R Soc Lond B Biol Sci. 2003; 358: 1669-1677. PMID: 14561325
51. Burkert K, Moodley K, Angel CE, Brooks A, Graham ES. Detailed analysis of inflammatory and neuromodulatory cytokine secretion from human NT2 astrocytes using multiplex bead array. Neurochem Int. 2012; 60: 573-580. doi: 10.1016/j.neuint.2011.09.002 PMID: 21939706
52. Carrero I, Gonzalo MR, Martin B, Sanz-Anquela JM, Arévalo-Serrano J, Gonzalo-Ruiz A. Oligomers of β-amyloid protein (Aβ1-42) induce the activation of cyclooxygenase-2 in astrocytes via an interaction with interleukin-1β, tumour necrosis factor-α, and a nuclear factor κ-B mechanism in the rat brain. Exp Neurol. 2012; 236: 215-227. doi: 10.1016/j.expneurol.2012.05.004 PMID: 22617488
53. Vallés S, Tsoi C, Huang WY, Wyllie D, Carlotti F, Askari JA, et al. Recruitment of a heparan sulfate sub-unit to the interleukin-1 receptor complex. Regulation by fibronectin attachment. J Biol Chem. 1999; 274: 20103-20109. PMID: 10400621
54. Bondareff W. Age-related changes in brain extracellular space affect processing of amyloid-β peptides in Alzheimer's disease. J Alzheimers Dis. 2013; 35: 1-6. doi: 10.3233/JAD-122305 PMID: 23364138
55. Sheng WS, Hu S, Min X, Cabral GA, Lokensgard JR, Peterson PK. Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia. 2005; 49: 211-219. PMID: 15390091
56. Esposito G, Scuderi C, Valenza M, Togna GI, Latina V, De Filippis D, et al. Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PLoS One. 2011; 6:e28668. doi: 10.1371/journal.pone.0028668 PMID: 22163051
57. Scuderi C, Esposito G, Blasio A, Valenza M, Arietti P, Steardo L Jr, et al. Palmitoylethanolamide counteracts reactive astrogliosis induced by β-amyloid peptide. J Cell Mol Med. 2011; 15: 2664-2674. doi: 10.1111/j.1582-4934.2011.01267.x PMID: 21255263
58. Puffenbarger RA, Boothe AC, Cabral GA. Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia. 2000; 29: 58-69. PMID: 10594923
59. Facchinetti F, Del Giudice E, Furegato S, Passarotto M, Leon A. Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia. 2003; 41: 161-168. PMID: 12509806
60. Ehrhart J, Obregon D, Mori T, Hou H, Sun N, Bai Y, et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation. 2005; 12: 2-29.
61. Castillo A, Tolón MR, Fernández-Ruiz J, Romero J, Martinez-Orgado J. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB (2) and adenosine receptors. Neurobiol Dis. 2010; 37: 434-440. doi: 10.1016/j.nbd.2009.10.023 PMID: 19900555
62. Martín-Moreno AM, Reigada D, Ramírez BG, Mechoulam R, Innamorato N, Cuadrado A, et al. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol Pharmacol. 2011; 79: 964-973. doi: 10.1124/mol.111.071290 PMID: 21350020
63. Martín-Moreno AM, Brera B, Spuch C, Carro E, García-García L, Delgado M, et al. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation. 2012; Jan 16 9:8. doi: 10.1186/1742-2094-9-8 PMID: 22248049
64. Esposito G, De Filippis D, Carnuccio R, Izzo AA, Iuvone T. The marijuana component cannabidiol inhibits β-amyloid-induced tau protein hyperphosphorylation through Wnt/β-catenin pathway rescue PC12 cells. J Mol Med. 2006; 84: 253-258. PMID: 16389547
65. Kainu T, Wikström AC, Gustafsson JA, Pelto-Huikko M. Localization of the peroxisome proliferator-activated receptor in the brain. Neuroreport. 1994; 5: 2481-2485. PMID: 7696585
66. Luna-Medina R, Cortes-Canteli M, Alonso M, Santos A, Martínez A, Perez-Castillo A. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J Biol Chem. 2005; 280: 21453-21462. PMID: 15817469
67. Bright JJ, Kanakasabai S, Chearwae W, Chakraborty S. PPAR Regulation of Inflammatory Signaling in CNS Diseases. PPAR Res. 2008;658520. doi: 10.1155/2008/658520
68. Kapadia R, Yi JH, Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-γ agonists. Front Biosci. 2008; 13: 1813-1826. PMID: 17981670
69. Landreth G, Jiang Q, Mandrekar S, Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics. 2008; 5: 481-489. doi: 10.1016/j.nurt.2008.05.003 PMID: 18625459
70. Bodles AM, Barger SW. Secreted β-amyloid precursor protein activates microglia via JNK and p38-MAPK. Neurobiol Aging. 2005; 26: 9-16. PMID: 15585341
71. Ho GJ, Drego R, Hakimian E, Masliah E. Mechanisms of cell signaling and inflammation in Alzheimer's disease. Curr Drug Targets Inflamm Allergy. 2005; 4: 247-256. PMID: 15853747
72. Wang HM, Zhao YX, Zhang S, Liu GD, Kang WY, Tang HD, et al. PPARgamma agonist curcumin reduces the amyloid-beta-stimulated inflammatory responses in primary astrocytes. J Alzheimers Dis. 2010; 20: 1189-1199. doi: 10.3233/JAD-2010-091336 PMID: 20413894
73. Chen YC, Wu JS, Tsai HD, Huang CY, Chen JJ, Sun GY, et al. Peroxisome proliferator-activated receptor gamma (PPAR-γ) and neurodegenerative disorders. Mol Neurobiol. 2012; 46: 114-124. doi: 10.1007/s12035-012-8259-8 PMID: 22434581
74. Aguirre-Rueda D, Guerra-Ojeda S, Aldasoro M, Iradi A, Obrador E, Ortega A, et al. Astrocytes protect neurons from Aβ1-42 peptide-induced neurotoxicity increasing TFAM and PGC-1 and decreasing PPAR-γ and SIRT-1. Int J Med Sci. 2015; 12: 48-56. doi: 10.7150/ijms.10035 PMID: 25552918
75. Sun Y, Bennett A Cannabinoids: a new group of agonists of PPARs. PPAR Res. 2007;23513. doi: 10.1155/2007/23513
76. Wallace DC. Mitochondrial defects in cardiomyopathy and neuromuscular disease. Am Heart J. 2000; 139: S70-S85. PMID: 10650320
77. Lesnefsky EJ, Moghaddas S, Tandler B, Kerner J, Hoppel CL. Mitochondrial dysfunction in cardiac disease: ischemia - reperfusion, aging, and heart failure. J Mol Cell Cardiol. 2001; 33: 1065-1089. PMID: 11444914
78. Chen Q, Vazquez EJ, Moghaddas S, Hoppel CL, Lesnefsky EJ. Production of reactive oxygen species by mitochondria: central role of complex III. J Biol Chem. 2003; 278: 36027-36031. PMID: 12840017
79. Abeti R, Duchen MR. Activation of PARP by Oxidative Stress Induced by β-Amyloid: Implications for Alzheimer's Disease. Neurochem Res. 2012; 37: 2589-2596. doi: 10.1007/s11064-012-0895-x PMID: 23076628
80. Marcus DL, Thomas C, Rodriguez C, Simberkoff K, Tsai JS, Strafaci JA, et al. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp Neurol. 1998; 150: 40-44. PMID: 9514828
81. Padurariu M, Ciobica A, Hritcu L, Stoica B, Bild W, Stefanescu C. Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease. Neuroscience Letters. 2010; 469: 6-10. doi: 10.1016/j.neulet.2009.11.033 PMID: 19914330
82. Pappolla MA, Chyan YJ, Omar RA, Hsiao K, Perry G, Smith MA, et al. Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol. 1998; 152: 871-877. PMID: 9546346
83. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-) Δ9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci. 1998; 95: 8268-8273. PMID: 9653176
84. Hampson AJ, Grimaldi M. Cannabinoid receptor activation and elevated cyclic AMP reduce glutamate neurotoxicity. Eur J Neurosci. 2001; 13: 1529-1536. PMID: 11328347
85. Chen Y, Buck J. Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism. J. Pharmacol. Exp. Ther. 2000; 293: 807-812. PMID: 10869379
86. Praticò D MY Lee V, Trojanowski JQ, Rokach J, Fitzgerald GA. Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J. 1998; 12: 1777-1783. PMID: 9837868
87. Keller JN, Kindy MS, Holtsberg FW, St Clair DK, Yen HC, Germeyer A, et al. Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. J Neurosci. 1998; 18: 687-697. PMID: 9425011
88. Sompol P, Ittarat W, Tangpong J, Chen Y, Doubinskaia I, Batinic-Haberle I, et al. A neuronal model of Alzheimer's disease: an insight into the mechanisms of oxidative stress-mediated mitochondrial injury. Neuroscience. 2008; 153: 120-130. doi: 10.1016/j.neuroscience.2008.01.044 PMID: 18353561
89. Dumont M, Wille E, Stack C, Calingasan NY, Beal MF, Lin MT. Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J. 2009; 23: 2459-2466. doi: 10.1096/fj.09-132928 PMID: 19346295
90. Esposito L, Raber J, Kekonius L, Yan F, Yu GQ, Bien-Ly N, et al. Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice. J Neurosci. 2006; 26: 5167-5179. PMID: 16687508
91. Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 1997; 12: 913-919. PMID: 9309469
92. Walther S, Mahlberg R, Eichmann U, Kunz D. 9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology. 2006; 185: 524-528. PMID: 16521031
93. Krishnan S, Cairns R, Howard R. (2009) Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev. 15;(2): CD007204. doi: 10.1002/14651858